scispace - formally typeset
R

Richard B. Gaynor

Researcher at Eli Lilly and Company

Publications -  156
Citations -  15354

Richard B. Gaynor is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Gene expression & Transcription factor. The author has an hindex of 63, co-authored 151 publications receiving 14557 citations. Previous affiliations of Richard B. Gaynor include Veterans Health Administration & University of Texas Southwestern Medical Center.

Papers
More filters
Journal ArticleDOI

The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β

TL;DR: The results indicate that the anti-inflammatory properties of aspirin and salicylate are mediated in part by their specific inhibition of IKK-β, thereby preventing activation by NF-κB of genes involved in the pathogenesis of the inflammatory response.
Journal ArticleDOI

Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs.

TL;DR: Results indicate that TDP-43 is capable of modulating both in vitro and in vivo HIV-1 gene expression by either altering or blocking the assembly of transcription complexes that are capable of responding to Tat.
Journal ArticleDOI

IκB kinases: key regulators of the NF-κB pathway

TL;DR: A better understanding of the mechanisms that activate this pathway provides the potential for defining new therapeutic targets that might prevent the aberrant activation of NF-kappaB in a variety of human diseases.
Journal ArticleDOI

Histone H3 phosphorylation by IKK-α is critical for cytokine-induced gene expression

TL;DR: It is shown that IKK-α functions in the nucleus to activate the expression of NF-κB-responsive genes after stimulation with cytokines, defining a new nuclear role of Ikk-α in modifying histone function that is critical for the activation ofNF-κBs-directed gene expression.
Journal ArticleDOI

Sulindac Inhibits Activation of the NF-κB Pathway

TL;DR: The results suggest that the growth inhibitory and anti-inflammatory properties of sulindac may be regulated in part by inhibition of kinases that regulate the NF-κB pathway.